 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Aspirin for the Prevention of Heart Attacks in People without Previous Cardiovascular Events: Recommendations from the United States Preventive Services Task Force
15 January 2002 | Volume 136 Issue 2 | Page I55
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full reports titled "Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale" and "Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force." They are in the 15 January 2002 issue of Annals of Internal Medicine (volume 136, pages 157-160 and pages 161-172). The first report was written by the U.S. Preventive Services Task Force; the second report was written by M Hayden, M Pignone, C Phillips, and C Mulrow.
What is the United States Preventive Services Task Force?
The United States Preventive Services Task Force (USPSTF) is a group of health experts that reviews published research and makes recommendations about preventive health care.
What is the problem and what is known about it so far?
Heart attack ("myocardial infarction") occurs when blockage develops in the blood vessels that supply the heart muscle. Heart attacks are one of the most common causes of illness and are the leading cause of death in the United States. Certain conditions ("risk factors") increase a person's chance of having a heart attack. They include older age, male sex, high blood pressure, diabetes, smoking, high total or LDL ("bad") cholesterol levels, low HDL ("good") cholesterol levels, and close relatives with heart attacks before age 60. Aspirin decreases the chances of a heart attack in people who have had previous heart attacks or strokes, but its usefulness in people without such a history is unclear. Aspirin can have uncommon but serious complications, such as bleeding in the digestive tract or in the brain.
How did the USPSTF develop these recommendations?
The USPSTF reviewed published research to measure the benefits and harms of aspirin use in adults who have never had a heart attack or stroke.
What did the authors find?
There is good evidence that aspirin decreases heart attacks in people who do not have cardiovascular disease but do have heart attack risk factors. The more risk factors a person has, the more heart attacks aspirin prevents. However, taking aspirin increases a person's chances of complications, such as bleeding in the digestive tract or brain. Complications are most likely in people who have uncontrolled high blood pressure or who take blood thinners or anti-inflammatory drugs in addition to aspirin.
What does the USPSTF suggest that patients do?
Adult patients who have cardiovascular risk factors should discuss the benefits and harms of aspirin to prevent cardiovascular events with their doctors. Patients and doctors can use a tool located at http://www.med-decisions.com to calculate a person's risk of a future heart attack. If a patient's chance of having a heart attack over the next 5 years is at least 3 out of 100 (3%), then the benefits of aspirin are likely to outweigh the harms. However, there is no single correct answer for all patients. The decision to take aspirin or not will depend on the patient's feelings about avoiding heart attacks while risking the possible complications of bleeding in the digestive tract or brain.
What are the cautions related to these recommendations?
Participants in the studies that the USPSTF used to develop the recommendations were mostly men who were 40 to 75 years of age. Estimates of benefits and harms may not be reliable for women or for older men.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  H. Ogawa, M. Nakayama, T. Morimoto, S. Uemura, M. Kanauchi, N. Doi, H. Jinnouchi, S. Sugiyama, Y. Saito, and for the Japanese Primary Prevention of Atheroscler Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial JAMA, November 12, 2008; 300(18): 2134 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U Bulugahapitiya, S Siyambalapitiya, J Sithole, D J Fernando, and I Idris Age threshold for vascular prophylaxis by aspirin in patients without diabetes Heart, November 1, 2008; 94(11): 1429 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Elwood and G. Morgan Aspirin for all over 50 revisited Heart, November 1, 2008; 94(11): 1364 - 1365. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, E. M. Quigley, R. A. Harrington, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1502 - 1517. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, and E. M. Quigley ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation, October 28, 2008; 118(18): 1894 - 1909. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Walsh and G. Spurling Aspirin in type 2 diabetes: is there any evidence base? BMJ, October 16, 2008; 337(oct16_1): a1902 - a1902. [Full Text]
|
|
|
|
 |
|
 J. L. Rosenzweig, E. Ferrannini, S. M. Grundy, S. M. Haffner, R. J. Heine, E. S. Horton, and R. Kawamori Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3671 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zaman Huri, Lee Qiu Yi, R. Pendek, and Che Zuraini Sulaiman Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients Journal of Pharmacy Practice, August 1, 2008; 21(4): 287 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Kahn, R. M. Robertson, R. Smith, and D. Eddy The Impact of Prevention on Reducing the Burden of Cardiovascular Disease Diabetes Care, August 1, 2008; 31(8): 1686 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kahn, R. M. Robertson, R. Smith, and D. Eddy The Impact of Prevention on Reducing the Burden of Cardiovascular Disease Circulation, July 29, 2008; 118(5): 576 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leshno, M. Moshkowitz, and N. Arber Aspirin is Clinically Effective in Chemoprevention of Colorectal Neoplasia: Point Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1558 - 1561. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Sandler Aspirin Should Not Be Promoted for Colon Cancer Prevention: Counterpoint Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1562 - 1563. [Full Text] [PDF]
|
|
|
|
 |
|
 U.S. Preventive Services Task Force Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, June 3, 2008; 148(11): 846 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Greving, E. Buskens, H. Koffijberg, and A. Algra Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk Circulation, June 3, 2008; 117(22): 2875 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rees, J. Stevenson, and on behalf of the British Menopause Society Council Primary prevention of coronary heart disease in women Menopause Int, March 1, 2008; 14(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mancia and G. Grassi Editorial: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 5 - 12. [PDF]
|
|
|
|
 |
|
 D. B. Hogan Defying dementia Can Fam Physician, February 1, 2008; 54(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Graff, N. von Hentig, K. Kuczka, C. Angioni, P. Gute, S. Klauke, E. Babacan, and S. Harder Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo J. Antimicrob. Chemother., February 1, 2008; 61(2): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hunt, D. Choquette, B. N. Craig, C. De Angelis, F. Habal, G. Fulthorpe, J. I. Stewart, A. G.G. Turpie, and P. Davis Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician, July 1, 2007; 53(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J E Parry Review: oral anticoagulants plus aspirin reduce arterial thromboembolism more than oral anticoagulants alone but only in patients with mechanical heart valves Evid. Based Nurs., July 1, 2007; 10(3): 79 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Budoff, L. J. Shaw, S. T. Liu, S. R. Weinstein, T. P. Mosler, P. H. Tseng, F. R. Flores, T. Q. Callister, P. Raggi, and D. S. Berman Long-Term Prognosis Associated With Coronary Calcification: Observations From a Registry of 25,253 Patients J. Am. Coll. Cardiol., May 8, 2007; 49(18): 1860 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U.S. Preventive Services Task Force* Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, March 6, 2007; 146(5): 361 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dube, A. Rostom, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association Circulation, January 2, 2007; 115(1): 114 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care, January 1, 2007; 30(1): 162 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Pearson The Prevention Of Cardiovascular Disease: Have We Really Made Progress? Health Aff., January 1, 2007; 26(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]
|
|
|
|
|
|
T Marshall, S Bryan, P Gill, S Greenfield, K Gutridge, and Birmingham Patient Preferences Group Predictors of patients' preferences for treatments to prevent heart disease Heart, November 1, 2006; 92(11): 1651 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. O'Kennedy, L. Crosbie, S. Whelan, V. Luther, G. Horgan, J. I Broom, D. J Webb, and A. K Duttaroy Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 170 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 B. M. Psaty and J. D. Potter Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med., August 31, 2006; 355(9): 950 - 952. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Becker, J. Segal, D. Vaidya, L. R. Yanek, J. E. Herrera-Galeano, P. F. Bray, T. F. Moy, L. C. Becker, and N. Faraday Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy JAMA, March 22, 2006; 295(12): 1420 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, March 7, 2006; 144(5): 326 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, E. W Steyerberg, and C. de Laet The polypill: at what price would it become cost effective? J Epidemiol Community Health, March 1, 2006; 60(3): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Nijhuis, T. Stijnen, A. Peeters, J. C.M. Witteman, A. Hofman, and M. G. M. Hunink Apparent and Internal Validity of a Monte Carlo-Markov Model for Cardiovascular Disease in a Cohort Follow-up Study. Med Decis Making, March 1, 2006; 26(2): 134 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein Primum non nocere: Antithombotics after intracerebral hemorrhage? Neurology, January 24, 2006; 66(2): 162 - 163. [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey COX-2 chronology Gut, November 1, 2005; 54(11): 1509 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Woolf, E. C.Y. Chan, R. Harris, S. L. Sheridan, C. H. Braddock III, R. M. Kaplan, A. Krist, A. M. O'Connor, and S. Tunis Promoting Informed Choice: Transforming Health Care To Dispense Knowledge for Decision Making Ann Intern Med, August 16, 2005; 143(4): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick and S. M. Weisman Risk of Hemorrhagic Stroke With Aspirin Use: An Update Stroke, August 1, 2005; 36(8): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
|
|
P. Elwood, G. Morgan, G. Brown, and J. Pickering Aspirin for everyone older than 50?: FOR BMJ, June 18, 2005; 330(7505): 1440 - 1441. [Full Text] [PDF]
|
|
|
|
|
|
|
Article
